Navigation Links
EUCODIS Bioscience Appoints Thomas Fischer as New CEO
Date:12/7/2009

VIENNA, Austria, December 7 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry, announced today that it has appointed Mr Thomas Fischer, currently CFO, as new CEO of the Company. Going forward, EUCODIS Bioscience' sole focus will be to provide high-performance enzymes to customers, capitalizing on the Company's experience in commercial enzyme development and on its proven technology of "in vivo recombination".

In line with this move EUCODIS Bioscience will spin out its French research subsidiary in a management buy-in lead by Rudy Pandjaitan, PhD, previously CEO of EUCODIS Bioscience.

Dr. Pandjaitan will acquire a majority stake in the new entity. Under his leadership the new entity will develop next-generation applications of "in vivo recombination". EUCODIS Bioscience will retain a strategic share in its former subsidiary.

"White Biotechnology, or enzyme-based products and manufacturing, is a 100 billion Euro market, and EUCODIS Bioscience is well positioned to exploit the huge commercial potential of this business", said Thomas Fischer, CEO of EUCODIS Bioscience. "It was under Rudy's leadership that the Company has developed into this position, and we are pleased that he will continue to actively support EUCODIS Bioscience in the area of business development as a consultant."

"EUCODIS Bioscience' technology is a powerful and proven tool for the creation of novel enzymes", said Dr. Pandjaitan. "Even more fascinating, in vivo recombination may also be used in synthetic biology, generating DNA strands of more than 10,000 base pairs on a routine basis. It is our vision that in vivo recombination will enable the creation of novel pathways and even whole genomes, providing a key technology for the 'cellular factory' of the future."

"In vivo recombination" is EUCODIS Bioscience' proprietary, patent-protected technology for the development of industrial enzymes with novel properties.

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, customizes, manufactures, and markets industrial enzymes.

EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with a subsidiary in Germany.

    For more information, please visit http://www.eucodisbioscience.com

    Company contact EUCODIS Bioscience:
    Thomas Fischer, MBA
    CEO
    EUCODIS Bioscience
    Campus Vienna Biocenter II
    Viehmarktgasse 2 a/ 2 OG
    A-1030 Vienna
    AUSTRIA
    +43-1-8900804
    office@eucodisbioscience.com

    Media contact EUCODIS Bioscience:
    Frank Butschbacher
    Investor Relations & Communications
    http://www.butschbacher.net
    +43-650-7844940
    office@butschbacher.net

SOURCE EUCODIS Bioscience


'/>"/>
SOURCE EUCODIS Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus
2. EUCODIS Bioscience Launches Lipase Portfolio
3. EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries
4. EUCODIS Bioscience Signs Research Agreement With Genencor
5. EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
6. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
7. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
8. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
9. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
10. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
11. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Non-profit Consortium Aims to Generate Genomic ... Research and Discovery --> --> ... plan to sequence 100,000 individuals. It is intended to initially ... 7 of North and East Asian countries. ... project will focus on creating phased reference genomes for all ...
(Date:2/11/2016)... , Feb. 11, 2016  Bioethics International, a not-for-profit ... are researched, developed, marketed and made accessible to patients around ... Open had named the publication of the Good ... The publication is also featured as one of BMJ ... the last year that are most frequently read. ...
(Date:2/11/2016)... SANTA CRUZ, Calif. , Feb. 11, 2016 /PRNewswire/ ... accepting applications to its beta program for a planned ... co-founder, will present the company,s metagenomic genome assembly method ... 2016 Advances in Genome Biology & Technology conference in ... novo  assembly of these highly complex datasets is difficult. ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... medicine, has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) ... phsyicians in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, ...
Breaking Biology Technology:
(Date:2/4/2016)... 4, 2016 The field of Human ... the most popular hubs of the biotechnology industry. ... huge studies of human microbiota, have garnered a ... the microbiome space has literally exploded in terms ... This report focuses on biomedical aspects of research, ...
(Date:2/3/2016)... February 3, 2016 --> ... research report "Automated Fingerprint Identification System Market by Component ... Application (Banking & Finance, Government, Healthcare, and Transportation) and ... the market is expected to be worth USD 8.49 ... between 2015 and 2020. The transformation and technology evolution ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
Breaking Biology News(10 mins):